13F Holdings
中文EN

BLRX BioLineRx Ltd. IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1498403 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-95.9%
TTM net income YoY13.0%
TTM EPS YoY100.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin80.5%
Operating margin-871.8%
Net margin-680.2%
FCF margin-686.4%
EBITDA margin-829.8%

Returns

ROE-50.7%
ROA-20.1%
ROIC (approx.)-90.4%
Asset turnover0.03x

Leverage & solvency

Liabilities / assets42.9%
Debt / equity0.00x
Current ratio1.95x
Interest coverage-8.22x

Cash quality & payout

Operating cash flow / net income1.01x
Accruals ratio0.1%
Payout ratio—
Capex / revenue2.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue$1.18M$28.94M$4.80M$0$0
Cost of revenue$230,000$9.26M$3.69M$0$0
Gross profit$950,000$19.68M$1.11M$0$0
R&D expense$8.09M$9.15M$12.52M$17.63M$19.47M
SG&A expense$3.14M$6.32M$6.31M$5.07M$4.31M
Operating income-$10.29M-$20.41M-$49.69M-$29.16M-$24.78M
Interest expense$1.25M$9.07M$2.14M$1.79M$984,000
Income tax$0$0$0$0$0
Net income-$8.03M-$9.22M-$60.61M-$24.95M-$27.05M
EBITDA-$9.79M-$19.98M-$49.11M-$28.54M-$24.12M
EPS (basic)0.00-0.01-0.06-0.03-0.04
EPS (diluted)0.00-0.01-0.06-0.03-0.04
Weighted avg. shares (diluted)2.47B1.20B963.37M——
Balance sheet
Cash & equivalents$3.25M$10.44M$4.25M$10.59M$12.99M
Receivables$46,000$2.48M$358,000$0—
Inventory$2.15M$3.15M$1.95M$0—
Current assets$23.68M$27.10M$47.18M$52.00M$57.40M
PP&E, netmay include right-of-use assets (IFRS)$160,000$386,000$473,000$726,000$952,000
Intangibles$16.37M$10.45M$14.85M$21.89M$21.70M
Total assets$40.91M$38.91M$63.92M$76.38M$81.39M
Current liabilities$12.12M$15.41M$42.78M$10.68M$9.72M
Short-term debt$4.48M$4.48M$3.15M$1.54M$2.76M
Total liabilities$17.56M$25.45M$50.70M$25.54M$13.30M
Shareholders' equity$18.20M$13.46M$13.22M$50.84M$68.09M
Cash flow statement
Operating cash flow-$8.07M-$43.87M-$22.61M-$26.24M-$23.57M
Capital expenditure$25,000$53,000$116,000$131,000$97,000
Free cash flow-$8.10M-$43.93M-$22.72M-$26.37M-$23.67M
Investing cash flow-$8.54M$29.37M$1.44M$4.01M-$38.22M
Financing cash flow$8.88M$20.66M$15.06M$20.44M$57.75M
Depreciation & amortization$495,000$431,000$583,000$615,000$660,000
Stock-based compensation$396,000$1.14M$2.32M$2.25M$1.50M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.